Published: July 01, 2008
OrthoLogic Joins Russell Microcap Index
TEMPE, Ariz., July 1, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. announced today that the Company was added to the Russell Microcap Index as part of the Russell Investment Group's reconstitution of its family of U.S. indexes on June 27, 2008. Membership in the Russell Microcap Index, which remains in place for one year, results in automatic inclusion in the appropriate growth and value style indexes. The Russell Investment Group determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
According to Russell Investments, the Russell Microcap Index is constructed to provide a comprehensive and unbiased barometer for the microcap segment trading on national exchanges. The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It includes 1000 of the smallest securities in the small-cap Russell 2000(r) Index based on a combination of their market cap and current index membership; it also includes the next 1,000 securities.
About OrthoLogic
OrthoLogic is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is focused on development and commercialization of two product platforms: AZX100 and Chrysalin(r) (TP508).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. Based on its demonstrated effects in pre-clinical models, AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary disease, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. OrthoLogic has an exclusive worldwide license to AZX100.
Chrysalin, the Company's novel synthetic 23-amino acid peptide, has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is being studied in disorders that involve vascular endothelial dysfunction. The Company owns exclusive worldwide rights to Chrysalin.
OrthoLogic's corporate headquarters are in Tempe, Arizona. For more information, please visit the Company's website: www.orthologic.com.
CONTACT: OrthoLogic
Investor Relations
Karen Struck
(602) 286-5250
kstruck@olgc.com
The Trout Group
Lauren Glaser
(415) 392-3310
lglaser@troutgroup.com
Search News
